{"filing":{"accession_number":"0001193125-26-264085","cik":"0001672619","ticker":"ELVN","company_name":"Enliven Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"d152745d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526264085/d152745d8k.htm"},"events":[{"id":5941,"run_id":5214,"accession_number":"0001193125-26-264085","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Enliven Therapeutics held its Annual Meeting of Stockholders on June 9, 2026, with voting results on five proposals: election of two Class III directors (Richard Fair and Lori Kunkel), ratification of Deloitte \u0026 Touche LLP as independent auditor, approval to increase authorized common shares from 100 million to 200 million, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency.","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5666,"accession_number":"0001193125-26-264085","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The Company increased authorized common shares from 100 million to 200 million following stockholder approval at the Annual Meeting on June 9, 2026. While this is a routine corporate governance matter (Item 5.03), the doubling of authorized shares is material to investors as it significantly expands the Company's capacity to issue equity, which could affect shareholder dilution and capital-raising flexibility. This does not fit neatly into the more specific event categories but warrants disclosure as a material amendment to the Certificate of Incorporation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:01:09.158684+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5667,"accession_number":"0001193125-26-264085","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the complete voting results from Enliven Therapeutics' Annual Meeting of Stockholders, including five proposals: election of two Class III directors (Richard Fair and Lori Kunkel), ratification of Deloitte \u0026 Touche LLP as independent auditor, approval to increase authorized common shares from 100M to 200M, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. The disclosure of shareholder voting outcomes on material corporate matters is the core purpose of Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:01:09.158684+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5666,"accession_number":"0001193125-26-264085","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The Company increased authorized common shares from 100 million to 200 million following stockholder approval at the Annual Meeting on June 9, 2026. While this is a routine corporate governance matter (Item 5.03), the doubling of authorized shares is material to investors as it significantly expands the Company's capacity to issue equity, which could affect shareholder dilution and capital-raising flexibility. This does not fit neatly into the more specific event categories but warrants disclosure as a material amendment to the Certificate of Incorporation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:01:09.158684+00:00","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-06-09"},{"id":5667,"accession_number":"0001193125-26-264085","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the complete voting results from Enliven Therapeutics' Annual Meeting of Stockholders, including five proposals: election of two Class III directors (Richard Fair and Lori Kunkel), ratification of Deloitte \u0026 Touche LLP as independent auditor, approval to increase authorized common shares from 100M to 200M, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. The disclosure of shareholder voting outcomes on material corporate matters is the core purpose of Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:01:09.158684+00:00","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-06-09"}]}